A. Anichini

Publications276
h-index54
Citations10,680
Highly Influential Citations310
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Parmiani
  • 582 Publications • 30,235 Citations
  • R. Mortarini
  • 137 Publications • 6,841 Citations
  • S. Rosenberg
  • 1,497 Publications • 208,544 Citations
  • S. Ferrone
  • 1,260 Publications • 42,354 Citations
  • Publications
  • Influence
Interleukin-12: Biological Properties and Clinical Application
TLDR
More effective application of this cytokine, and of newly identified IL-12 family members (IL-23 and IL-27), should be evaluated as therapeutic agents with considerable potential in cancer patients.
View on Publisher
Role of macrophage targeting in the antitumor activity of trabectedin.
View on PubMed
Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
TLDR
These results suggest a crucial role of TAM reprogramming, upon Fc receptor engagement by ICI, eventually inducing HP and provide clues on a distinctive immunophenotype potentially able to predict HP.
View on Publisher
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
TLDR
Results suggest that targeted inhibition of Axl signaling in the subset of melanomas lacking MITF and MDAs may represent a novel therapeutic strategy.
View on PubMed
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.
TLDR
It is shown that human melanoma cell lines derived from LN metastases express ligands for natural cytotoxicity receptors (NCRs) and DNAX accessory molecule-1 (DNAM-1), two emerging NK cell receptors key for cancer cell recognition, but not NK group 2 member D (NKG2D).
View on PubMed
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
TLDR
Interestingly, protein levels did not always correlate with ALK genetic alterations and/or mRNA abundance, however, wild-type ALK receptor requires a critical threshold of expression to achieve oncogenic activation.
View on PubMed
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
TLDR
The available human TAA peptides, the potential immunogenicity (i.e., the ability to trigger a tumor-specific T-cell response) of T AA peptides in vitro and ex vivo, and the potential to construct slightly modified forms of Taa peptides that have increased T- cell stimulatory activity are analyzed.
View on PubMed
An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does…
TLDR
Expansion of peripheral immune repertoire to Melan-A/Mart-1 takes place in some metastatic patients and leads to enhanced CTL induction after antigen-presenting cell–mediated selection, but, in most metastatic lesions, it does not overcome tumor escape from immune surveillance.
View on PubMed
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
TLDR
It is indicated that pembrolizumab could be a worthwhile neoadjuvant therapy for the treatment of MIBC when limited to patients with PD-L1-positive or high-TMB tumors.
View on PubMed
BRAF alterations are associated with complex mutational profiles in malignant melanoma
TLDR
The p16/ARFΔ+BRAF/RAS profile was significantly associated with a longer survival, while complex mutational profiles were detected in highly aggressive disease and poor survival, suggesting that a more extensive molecular classification of melanoma would significantly impact its clinical management.
View on Springer
...
...